This manuscript provides an overview of how to interpret in vitro clotting studies and how to selec t studies to evaluate patients with bleeding disorders in the ICU. It provides a practical approa ch to understanding the complex subject of clotting factor abnormalities, including the most common problems of preanalytical error and anticoagulation therapy. Limitations and pitfalls of diagnostic testing are highlighted.
C
oncerns about the risk of bleeding in critically ill patients are common. This apprehension may stem from a sense of responsibility for bleeding following procedures or anticoagulant therapy, or perhaps the fact that hemorrhage is often visible externa lly. In addition, the clinical laboratory may raise awareness by offering tests that clinicians think provide information about impaired clotting. Unfortunately, many intensivists are not skilled or trained in carrying out assessments of coagulation testing or disorders. As the second of a two-part series on coagulopathy in critically ill patients, this article reviews soluble clotting factors and the most frequent coagulation disorders seen among adults in the ICU. Although this article does not discuss thrombophilia in detail, it does provide a framework for understanding hemostatic testing and interpreting common coagulation tests.
Evaluating Classic Clotting Pathways
Many critical care physicians have little more than superfi cial knowledge of clotting pathways because they are hard to remember, with confusing nomenclature and redundant terminology ( Table 1 ). In addition, in-depth knowledge is usually not necessary on a daily basis. Clotting factors were numbered in the order of their discovery, adding to the seemingly nonsensical sequence of activation. Furthermore, the historically taught concept that there are two distinct pathways by which blood clots is an artifi cial and misleading construct. In the body, physiologic clotting is the result of the activation of the tissue factor pathway (formerly called the extrinsic pathway), a process that is amplifi ed by the contact activation pathway (formerly called the intrinsic pathway). Two separate, merging pathways were popularized predominately for purposes of understanding the sequence of clotting events in the laboratory. Nonetheless, comprehending these pathways is necessary to accurately interpret laboratory values, avoid acting on spurious results, and forgo unnecessary testing. For example, the activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are habitually linked in some clinicians' minds, resulting in unnecessary testing and confusing results.
Common Laboratory Assays
The PT monitors the tissue factor pathway and common portions of the clotting pathway ( Fig 1 ) . The factor) is added, followed by reversal of the citrate effe ct with calcium. As shown in Figure 2 , the particulate activates factor XII, which activates factor XI, then IX, and VIII, which then activates the common sequence of factor X through fi brin formation. As with the PT, the result is reported in seconds. Maybe becau se the sequence is lengthier or the concentration of each factor is lower, single factors unique to the contact activation pathway must decline to only 15% to 30% of normal before the aPTT is prolonged. Milder defi ciencies of multiple factors can also prolong the aPTT, and as a result it is usually a more sensitive measure of factor changes, especially factors VIII and IX. Prekallikrein, high-molecular-weight kinino gen (HMWK), antiphospholipid antibodies, and factor XII defi ciencies will also prolong the aPTT, but the former two are rare, and none of the four increa ses the risk of bleeding, despite altering the aPTT. In fact, patients with antiphospholipid antibodies PT is relatively easy to understand: citrate anticoagulated plasma is centrifuged to remove platelets (centrifugation removes the effect of platelets on clotting, isolating the role of soluble clotting factors), then tissue factor (a complete thromboplastin) and calcium are added to activate clotting. This procedure preferentially activates factor VII, which in turn activates factors X, V, and II (prothrombin), which converts fi brino gen (factor I) to fi brin, which is detected using optical or electrical methods and reported in seconds. Perhaps because there are fewer steps in the sequence or because factor VII circulates in the highest concentration of any factor, the PT is relatively resistant to change, typically requiring single-factor levels to fall to 10% of normal or less before becoming prolonged. As seen in Figure 1 , there is only a single factor unique to this pathway, and selective factor VII defi ciency is the only way the PT can be prolonged without impacti ng the aPTT. Because the sensitivity of reagen ts varies between laboratories and sometimes even within a hospital over time, PT is referenced to an international standard (the international normalized ratio [INR] ). 1 Use of the INR allows patients who are therapeutically anticoagulated with warfarin to have their anticoagulation intensity interpreted in a standardized fashion. Because the INR calibration was developed using patients with stable warfarin anti coagulation, its applicability to other causes of an elevated PT, like liver failure, is uncertain. 2 The aPTT is more complex, but hints to understanding this test, which monitors the contact activation and common pathways, are apparent from its name. A particulate contact activator (eg, ellagic acid, kaolin, celite, or silica), is added to platelet-poor, citrated plasma substrate, hence the designation "activated." A "partial thromboplastin" (lacking tissue mality can be detected using additional tests: the Russell's viper venom assay, and the thrombin time (TT) or Reptilase time assays. The viper venom assay direct ly activates factor X, testing the complete common pathway. The TT and Reptilase time determine the speed with which fi brinogen is converted to fi brin in response to exogenous thrombin; hence, they test only the suffi ciency and functionality of fi brinogen and help distinguish patients with hypofi brinogenemia or dysfi brinogenemia. 5 The main difference betw een the TT and the Reptilase time is that the latter is not altered by the presence of heparin. Alternatively, the quantity of fi brinogen can also be evaluated by direct assay. Such tests can sometimes be useful following massive transfusion when hypofi brinogenemia is suspected. The bleeding time is a relatively crude test in which a standardized skin wound is made with a lancet and the time for blood to clot is recorded as the lesion is gently dabbed with gauze. It is alleged to measure the combined effects of tissue integrity, platelet function, and soluble clotting factor adequacy, with an emphasis on adequacy of platelet function. This test is highly subject to variations in technique, and correlates poorly with other in vitro tests, except that it can be guaranteed to be prolonged when platelet counts decline below 50 3 10 9 /L. 6 Bleeding time testing has largely been abandoned in the ICU because it is diffi cult to perform, labor intensive, and a poor predictor of bleeding in the clinical setting.
Tests of Fibrinolysis
The term "fi brin degradation product" (FDP) is a general one that describes the breakdown products of fi brin and fi brinogen generated by the enzymatic action of plasmin. The D-dimer is a more specifi c FDP resulting only from degradation of fi brin from an intact clot, whereas a nonspecifi c FDP or fi brin split-product assay could be positive without a clot. Unfortunately, both assays lack specifi city and are positive not only in patients with thrombotic diseases (eg, venous thromboembolism, myocardial infarction, and disseminated intravascular coagulation [DIC] ), but can also be elevated in surgical, cancer, and pregnant patients. Because of impaired hepatic clearance, chronic liver disease can also result in elevated FDPs. Given this list of conditions, FDP assays are usually not very helpful in ICU patients. Commercially available assay methods differ signifi cantly (ie, latex or red blood cell agglutination or enzyme-linked immunosorbant assays), resulting in widely divergent sensitivities. If using a D-dimer assay as an adjunctive test for ruling out thromboembolic disease, it is imperative to use an ultrasensitive assay to avoid false-negative results. Tests using latex agglutination methods tend to be the least sensitive, with enzyme-linked immunosorbant are prone to thrombotic events despite having an elevated aPTT.
One test being used with increasing frequency because of the popularity of low-molecular-weight heparin (LMWH) therapy is the anti-Xa activity assay. The anti-Xa assay may have another advantage in that it is also less susceptible to infl uence by acute phase reactants, especially factor VIII, than the aPTT. The methodology is straightforward but unfamiliar to most physi cians: an excess of factor Xa and antithrombin are added to platelet-poor, citrated patient plasma. If there is any heparinoid in the patient sample, it binds to the exogenous antithrombin and inhibits the activity of the added Xa. This inhibition of Xa is detected as a decrea se in the cleavage of an added chromogenic substrate relative to the amount cleaved without the patient plasma. The primary reason the anti-Xa assay exists is because LMWHs and direct Xa inhibitors such as fondaparinux bind to antithrombin through a 5-oligosaccharide seque nce, but do not have suffi cient length to bind to thrombin (factor IIa). For this reason, the aPTT is less sensitive to LMWH than to unfractionated heparin (UFH). Contrary to common belief, antiXa inhibitors do prolong the aPTT and PT minimally (on average 1-4 s), but because these drugs cannot efficiently bind thrombin, clotting times are not altered as much as with UFH. Because of the predictability of anticoagulation using weight-based LMWH therapy, monitoring is rarely necessary. Potential candidates for whom anti-Xa monitoring might be considered are patients at the extrem es of weight, those with a glomerular fi ltration rate , 30-50 mL/min, and patien ts with higher renal clearance than expected as a result of increased cardiac output (eg, pregnant women and neonates). 3, 4 
Specialized Assays
In locations like the cardiac catheterization laboratory, where a real-time estimate of clotting is necessary, the activated clotting time (ACT) is often used, especially to monitor UFH or bivalirudin activity. The ACT is a nonspecifi c test that reports the time for an activating agent (eg, celite, kaolin, glass particles) to produce a clot in whole blood, thereby evaluating soluble factor and platelet function in toto . Because neither the reagents nor the clot detection method (eg, resistance to mechanical deformation of a clot or changes in the electrical or mechanical properties of the blood) are standardized, results of different assay systems are not equivalent, and the ACT correlates poorly with aPTT, PT, and anti-Xa assays.
As shown in Figure 2 , abnormalities of factors X, V, II, and fi brinogen alter both the PT and aPTT by impairi ng the shared common pathway. If clinically important, a specifi c common factor pathway abnor-transferring blood from a syringe to an anticoagulantcontaining tube, or failure to mix blood in with the anticoagulant all will artificially prolong the PT and aPTT. Conversely, hemolysis or excessively vigorous agitation of blood with citrate will artifi cially shorten the PT and aPTT. 12 Excessive tourniquet time will elevate von Willebrand Factor and factor VIII levels, resulting in falsely shortened PT and aPTT assay results. Because factor VII is temperature sensitive, cooling will also falsely shorten the PT, but will leave the aPTT unaffected, unless the patient is receiving heparin. 13 Since both the aPTT and PT are performed on plateletdepleted plasma, thrombocytopenia does not alter their in vitro value.
Soluble Clotting Factor Disorders

Introduction
The prevalence of inherited defi ciencies of single clotting factors ranges from 0.5 to 2 per million persons. 14, 15 Many of these congenital disorders are diagnosed in childhood following a major bleeding episode. However, patients with von Willebrand disease may not present with a bleeding diathesis until adulthood. In addition, some clotting factor defi ciencies resulting in thrombophilia, such as protein C or protein S defi ciencies, in addition to factor V leiden, may not become apparent until adulthood.
Most soluble clotting disorders in the adult ICU are acquired and involve multiple clotting factor abnormalities. As a result, the majority of these acquired conditions, including those caused by the use of exogenous anticoagulants, will alter both the PT and the aPTT. All clotting test abnormalities must be evaluated in the clinical context as there is no unique interpretation of a laboratory result. The hemostatic laboratory values seen in some of the more common critical illnesses are compared in Table 3 . In addition, there are numerous situations in which prolongation of an in vitro clotting test either has no influence on clinical bleeding or actually may increase the tendency for thrombosis. For example, the rare deficiency of the cofactor HMWK dramatically prolongs the aPTT but has no effect on bleeding predilection, while antiphospholipid antibody syndrome also prolongs the aPTT but predisposes patients to thromboses. Thus, not all PT and aPTT prolongations in vitro equate to an increased bleeding tendency. On the other hand, defi ciencies in other soluble factors, such as protein C or protein S, may predispose patients to abnormal clot formation. The prevalence of a hereditary propensity for clotting is substantial but often not evaluated. A discussion of inherited thrombophilia is beyond the scope of this article and can be found elsewhere. 16, 17 assay methods being more sensitive but also more time consuming and expensive.
Causes of Abnormal Clotting Assays
Surprisingly, the most common cause of an abnormal clotting assay is not a physiologic problem, or even a laboratory mistake, but rather an improperly obtained sample. There are several common causes of this so-called "preanalytical error" ( Table 2 ) . Accurate results from aPTT and PT tests require a specifi c ratio (9:1) of plasma to an anticoagulant, typically sodium citrate, in a "blue-stoppered" tube. If the tube is underfi lled, both results will be prolonged. Conversely, if the tube is forcefully overfi lled, clotting times will be shortened. 7 In addition, if polycythemia is present, the amount of plasma in the sample will be reduced compared with that of a patient with a normal hematocrit. This will result in a relative excess of the citrated anticoagulant solution and artifi cial prolongation of the clotting times. 8 Another potential source of error is blood contaminated with another anticoagulant during collection. This error occurs in one of two ways: the blood is drawn from a heparin-containing catheter without removal of suffi cient volume to clear the dead space, [9] [10] [11] or blood is placed into the wrong tube and then transferred to the correct tube. For example, blood initially drawn into a "purple-top" ethylenediaminetetraacetic acid -containing tube or a "green-top" heparin-containing tube and then transferred to a citrate tube will yield prolonged PT and aPTT values. Another problem results when blood is not promptly and gently mixed with citrate. For example, initial collection of blood into a tube not containing anticoagulant, delay in argatroban, or human recombinant activated protein C (rhAPC). Heparin is the prototypical example as it binds to antithrombin and thereby inhibits the actions of factors XII, XI, IX, X, and II. Because three of these factors (IX, XI, XII) are exclusive to the contact activation pathway and are more sensitive to heparin effects than the two factors in the common pathway (X and II), heparin alters the aPTT to a greater degree than the PT. In the event one suspects inadvertent contamination of a specimen with heparin (or LMWH), it is possible to add heparinase as an in vitro reversing agent. Heparin as a cause for a prolonged aPTT can also be effectively ruled out with a normal TT; since the TT is very sensitive to heparin, a normal result is exclusionary. Very high heparin levels, as might occur shortly after an UFH bolus or with an accidental overdose, will inhibit factors II and X, resulting in a prolongation of both the PT and aPTT. Endogenous clotting disorders rarely result in an aPTT greater than 100 s; hence, when aPTT of that magnitude is encountered, the cause is almost always heparin. When approv ed for the treatment of severe sepsis with high risk of death, rhAPC represents a special case in that it has a half-life of between 10 and 15 min, so that aPTT testing performed quickly after the specimen is obtained is substantially more prolonged than when the same specimen is tested as little as 15 to 30 min later. 19 Although common experience suggests an association between bleeding risk and degree of aPTT prolongation, scant data are available confi rming this correlation. An excessive amount of any anticoagulant may cause bleeding, and the treatment is intuitive;
Isolated PT Abnormalities
As shown in Figure 1 , an isolated abnormality of the tissue factor (extrinsic) pathway, measured by the PT assay, can only result from a factor VII abnormality. Although an autosomal recessive factor VII deficiency has been reported, it is exceedingly rare. 18 Since factor VII is synthesized in the liver and has a half-life of just 4 to 6 h, incipient liver failure or the initial stages of warfarin anticoagulation can cause a transient isolated PT abnormality. However, within days of liver failure onset or warfarin use, both the aPTT and PT will be prolonged as other hepatically produced factors IX, X, and II will also be depleted, despite having longer half lives. Since the production of factor VII is highly dependant on vitamin K, mild vitamin K defi ciency, secondary to poor nutrition or prolonged use of broad spectrum antibiotics, may prolong only the PT and not the aPTT. However, in more severe vitamin K defi ciency, both the PT and aPTT will be prolonged as a result of the effect on the other vitamin K-dependent clotting factors.
Isolated aPTT Abnormalities
Currently, aPTT methods are not standardized in a manner similar to the INR. As such, differences in local instrument calibrations and reagents result in variations in testing results, and clinicians should be familiar with the normal values for their local laboratories. In a properly collected sample, the most common cause of an isolated aPTT prolongation (contact activation pathway) is the presence of UFH, hirudin, can be used to treat factor IX defi ciency. Outside the United States, factor XI and XIII concentrates are also available options. 20 Any clinician caring for a patie nt with a suspected or proven single-factor deficiency should consult a coagulation specialist because the treatment is complex, expensive, and potentially dangerous.
Combined PT and aPTT Abnormalities
Most clotting disorders will affect both the PT and aPTT because components of the common pathway will either be inadequately produced or consumed in excess of their production. The easiest disorders to understand are those in which there is simple underproduction. Since all clotting proteins except factor VIII are produced by the liver, logically, hepatic failure is a common cause of dual assay abnormalities. Likewise, dietary defi ciency or warfarin exposure will impair hepatic production of vitamin K-dependent proteins (II, VII, IX, X), three of which are in the common pathway. Simply replacing the missing factors with fresh-frozen plasma will correct the clotting test of either condition. However, if established liver failure is the cause, correction will be transient, lasting only about one day, as the clotting factors are consumed without the production of new ones. In contrast, nutritional defi ciency or warfarin effect is promptly reversed by replacing vitamin K. Differentiating warfarin use from hepatic insuffi ciency is usually easily done with a clinical history. However, the two conditions can also be distinguished by measuring clot degradation products (eg, fi brin split products, D-dimer) or fi brinogen levels or activity (see Table 3 ). All should be normal with warfarin use. In distinction, severe hepatic disease often results in the inability to clear clot degradation products, raising D-dimer levels. Even when synthetic defi cits are corrected, this impaired clearance activity can produce in vitro clotting study prolongations. Elevated bilirubin and transam inase levels with reduced albumin concentrations also support a diagnosis of liver disease.
As mentioned in the "Isolated aPTT Abnormalities" section, heparin, in low doses, has the greatest effect on factors XII, XI, and IX. Hence, the aPTT is preferentially affected over the PT. Large heparin doses, however, also inhibit both factor Xa and thrombin-mediated conversion of fi brinogen to fi brin. Both of these inhibitions disrupt the common pathway of the coagulation cascade, resulting in prolongation of both the PT and aPTT. In some laboratories, heparinase is routinely added to blood undergoing PT testing to neutralize any heparin effects. A clinical history alone is almost always suffi cient to distinguish heparin exposure from that of warfarin or liver disease, but if laboratory confi rmation is needed, heparin exposure is associated with normal stopping the medication in most cases reverses anticoagulation in minutes to hours. If there is urgency to reverse the effects of UFH or to a lesser extent LMWH, protamine sulfate can be used as an antidote. Typically, doses of 1 mg of protamine for each 100 units of residual heparin are recommended, but practically, it is diffi cult to determine how much heparin activity remains. Protamine does not reverse the effects of fondaparinux.
The aPTT will also be prolonged by inhibitors to contact activation pathway components. Such inhibitors are usually antibodies directed against phospholipid (ie, lupus anticoagulant, anticardiolipin) or, less commonly, specifi c clotting factors. Inhibitors can be detected by performing a mixing study in which the patient sample is mixed with an equal volume of normal plasma. However, since the presence of an anticoagulant mimics the presence of an inhibitor, care should be taken to ensure samples sent for mixing studies are not contaminated with anticoagulants. If the sample contains inhibiting antibodies, the aPTT of the mixture will remain abnormal, whereas the aPTT will normalize if a simple defi ciency exists. (A deficiency state is corrected because the mixing study produces at least a 50% concentration of each factor, a quantity suffi cient for a normal aPTT). The one exception to this rule is that mixing studies typically result in an initially normal aPTT in the presence of antifactor VIII antibodies, but with prolonged incubation, the aPTT becomes prolonged. If clinically benefi cial, specifi c-factor assays can be performed to identify the defi ciency. It is sometimes a clinical challenge to monitor heparin anticoagulation in patients with antiphospholipid antibodies because the aPTT may be prolonged at baseline or may demonstrate an exaggerated prolongation when heparin is started. In either case an anti-Xa activity assay can be used for UFH monitoring.
As can be seen from Figure 2 , an inhibitor or deficiency of factors VIII (hemophilia A), IX (hemophilia B), XI, or XII may also produce an isolated aPTT abnormality, but probably only if levels are suffi ciently low. In theory, such defi ciencies can be corrected using fresh-frozen plasma, but doing so is ineffi cient and exposes recipients to risks of infection, volume overload, and transfusion reaction. Although cryoprecipitate is a more concentrated source of factor VIII and von Willebrand's factor, recombinant factors VIII or IX are commercially available and free of human plasma, and thus free from infection transmission risks. In addition, since these can be given in a small volume, they have become the preferred therapies. For patients who have acquired antibodies to factor VIII, bypassing agents or human recombinant activated factor VII can overcome the functional defi ciency of factor VIII. In addition, prothrombin complex, available in 15 or more brands worldwide, For severe sepsis, use of rhAPC has been shown to decrease markers of infl ammation and accelerated coagulation, and that action is associated with improv ed clinical outcomes. 23 Acute promyelocytic leukemia is the most common cancer associated with DIC and is another example in which specifi c therapy is available. In acute promyelocytic leukemia, promyelocytes bear a surface tissue factor-like molecule that activates the tissue factor pathway and also expre ss a receptor for plasminogen, resulting in primary fi brinolysis. 24, 25 In addition to supportive therapy with platelet and clotting factor transfusions (either using cryoprecipitate or fresh-frozen plasma), all-transretinoic acid therapy has been shown to shorten the duration of the coagulopathy. All-trans -retinoic acid therapy accelerates the differentiation of the malignant cells, resulting in a downregulation of the expression of the tissue factor and other procoagulant surface antigens. [26] [27] [28] Dilutional coagulopathy also can result in prolongation of both the PT and aPTT since all clotting factors are diluted. Although commonly reported in trauma patients, dilution of the clotting factors can result from any major bleed that requires massive transfusions. Correction of the PT and aPTT can be accomplished by replacing the clotting factors through the use of fresh-frozen plasma or fresh whole blood.
Monitoring Acute Therapeutic Anticoagulation
Monitoring Warfarin
Although warfarin depletes factor VII within 24 h, thereby prolonging the PT, the patient remains at risk for clot propagation or recurrence until all vitamin K-dependent clotting proteins are depleted, including factor IX (t 1/2 of 24 h), factor X (t 1/2 of 48 h), and factor II (t 1/2 of nearly 60 h). For this reason, some form of heparin or factor Xa inhibitor is necessary for at least a few days. 29 The PT is indexed to a worldwide standard and reported as the INR to allow direct comparisons between laboratories. 30 The risks of bleeding and PT prolongation are reasonably correlated, but the correlation does not appear to be linear. For example, the risk is relatively low until the INR exceeds 3 but increases exponentially when the INR exceeds 10. 31 Numerous other factors come into play: defi ciencies of platelet numbers or function, advanc ed age, alcoholism, heart failure, and hypertension all appear to signifi cantly increase the risk of bleeding with a prolonged PT. [32] [33] [34] [35] [36] fi brinogen levels and FDPs (unlike liver disease), and warfarin exposure is associated with a normal TT (unlike heparin). In addition, the effects of heparin can be neutralized in vitro with heparinase, if needed to help make the differentiation.
In the ICU, DIC is probably the single most common cause of dual pathway abnormalities. It is a condition in which clotting factors and platelets are consumed, clot degradation products are released, and eventually even anticlotting proteins are exhausted. 21 Regardless whether triggered by severe sepsis, trauma, or tumor, the initial stimulus to clot results in the progressive depletion of all clotting factors through consumption. FDPs also interfere with platelet function and fi brin formation, and in this way, further aggravate the accelerated clotting process. As platelets are destroyed, platelet factor 4 can be release d, and in some settings, this can lead to diagnostic confusion between DIC and heparin-induced thrombocytopenia . 21 Although DIC is typically viewed as a bleeding problem, it is the formation of microvascular thrombi that can damage red blood cells, forming schistocytes, and insidiously lead to tissue ischemia. Thrombosis in DIC is initially offset by key anticlotting protein systems: tissue factor pathway inhibit or counteracts effects of activated factor IX and X, the protein C-S complex inhibits activity of activated factors V and VIII, and general proteinase inhibition is accomplished by antithrombin and other lesser proteins. Simulta neously, activation of endogenous thrombolytic pathways, including plasminogen, occurs in an attempt to dissolve these thrombi. However, unless the stimulus is corrected, progressive clotting factor consumption occurs, eventually leading to a severe defi cie ncy state.
By depleting all clotting factors, DIC can increase both the PT and aPTT values, reduce fi brinogen levels, and elevate levels of clot degradation products. It has been empirically observed that the PT is prolonged more than the aPTT, 22 possibly as the result of the short half-life of factor VII. In a substantial percentage of DIC cases, however, the process is suffi ciently tame that neither the PT nor the aPTT is prolonged and fi brino gen levels can remain in the normal range. FDPs and/or D-dimer levels should be elevated in all cases of DIC. A vast array of other markers of accelerated coagulation are available, including prothrombin fragment 1.2, fi brinopeptide A, fi brin monomers, and thrombin-antithrombin complexes, but it is not clear whether any of these tests augment clinical care. The same can be said for tests of fi brinolysis such as plasminogen and antiplasmin levels.
Although the age-old maxim that the best treatment of DIC is to reverse the underlying cause is true, it is often not feasible. Nonetheless, specifi c treatments exist for DIC arising from certain etiologies. may better refl ect the actual level of anticoagulation. The pharmacokinetic profi le of LMWH in critically ill patie nts is uncertain, with some reports indicating impai red bioavailability 41, 42 and others reporting that renal insuffi ciency does not lead to drug accu mulation. 43 Hirudin, lepirudin, bivalirudin, and argatroban inhib it activated factor II (thrombin) and can thus be monitored using the aPTT. Although it can be monitored using the aPTT, bivalirudin is used predominately in cardiac and vascular interventions, and as such is more commonly monitored using the ACT. Furthermore, in the absence of renal insuffi ciency, monitoring of anticoagulation with bivalirudin is rarely necessary. Data suggest an imperfect relationship between drug concentrations and the aPTT, with the test becoming less responsive at high drug concentrations. The clinician must become familiar with the drug specifi cs before using any of these compounds, but as a general rule an aPTT similar to that of UFH (1.5-3 times the mean baseline) is the goal. Monitoring is usually started approximately 3 to 4 h after initiating dosing and performed less frequently as the aPTT enters the goal range and stability is demonstrated. Once stabilized, daily monitoring is suffi cient, provided renal function is unchanging. Like heparins, hirudin and lepirudin doses need to be reduced in the presence of renal insuffi ciency. Bivalirudin is predominately cleared by plasma peptidases with an additional renal component, allowing more freedom of dosing in renal insuffi ciency. In contrast, argatroban is cleared largely by the liver and needs dose reductions for patients with hepatic insuffi ciency.
Coagulation Tests and Procedures
One of the common uses of hemostatic testing is to evaluate the adequacy of coagulation and appropriateness of a patient for either surgery or invasive procedures. This is especially true for patients taking anticoagulant medicines and those with conditions known to produce abnormalities in these laboratory tests, such as hepatic insuffi ciency. The "acceptable" level of coagulation (or anticoagulation) for a procedure is dependent on both the nature of the procedure (ie, elective operation vs emergent bedside procedure) and the ease and safety in which the coagulation abnormality can be corrected. Since patien ts hardly ever undergo elective surgical procedures while they are critically ill, the following discussion will focus on urgent and emergent procedures. The safety of correcting the abnormality must include an evaluation of both the risk of bleeding from anticoagulation during the procedure as well as the risk of clotting while off anticoagulation for the procedure in
Monitoring Heparinoid Therapy
In addition to its diagnostic value, the aPTT is also commonly used to monitor the effects of several anticoagulants, including heparin, hirudin, lepirudin, bivalirudin, and argatroban. The aPTT is monitored during UFH infusions because a UFH-antithrombin complex inhibits the actions of factors II, IX, X, XI, and XII. Clinicians are sometimes puzzled that heparin does not prolong the PT, even though it inhibits the actions of factors X and II, which are both part of the tissue factor pathway; the explanation is not simple, some PT assay systems contain a heparinneutralizing compound, and in assays that do not remove heparin, heparin interacts with more components of the contact activation pathway than the tissue factor pathway. The aPTT is not an ideal monitoring tool for heparinoids because it is subject to numerous nonheparin infl uences. For example, many acute phase reactants, includ ing fi brinogen, can bind and neutralize UFH. In addition, factor VIII is not only an acute phase reactant, but also shortens the aPTT in vitro , occasionally leading clinicians to conclude that patients are resistant to the effects of UFH. In these cases, an anti-Xa assay or heparin level assay reveals whether the patient is adequa tely anticoagulated. Heparin resistance can occu r in patients with antithrombin defi ciency. However, the appearance of heparin resistance is much more likely to be the result of inadequate dosing or nonspecific acute phase reactants than from antithrombin defi ciency. 37 Although there is some variation by laboratory, the typical aPTT target is 1.5 to 2.5 times the average normal aPTT and roughly corresponds to an anti-Xa level of 0.3 to 0.7 units/mL. Checking an initial aPTT roughly 6 h after initiating therapy is importa nt to ensure prompt adequate anticoagulation. The use of a heparin dosing protocol, especially if adminis tered by a dedicated anticoagulation service, is a key to rapid, safe, effective anticoagulation. 38, 39 All forms of heparin are subject to at least partial renal clearance; hence, dose reductions are necessary when glomerular fi ltration rates fall below 30 to 50 mL/min. For the LMWHs, dose reductions should follow the manufacturer's recommendations, and an anti-Xa assa y must be performed if monitoring is desired. 40 Since LMWHs inactivate factor Xa with little effect on thrombin, they will not prolong (much) the aPTT, which is prone to variability due to alterations to nonthrombin components. However, laboratory monitoring is usually not required because the anticoagulant response to a fi xed-dose LMWH is highly correlated with the patient's body weight. Following the aPTT is usually suffi cient for UFH, but when seemingly high heparin doses are required, checking either an antiXa activity assay or directly measuring heparin levels
Conclusion
Tests of coagulation are often abnormal in critically ill patients. Unfortunately, many of these abnormal results are artifactual. When true, clotting test abnormalities can be associated with bleeding or clotting complications and are associated with worse patient outcomes. Abnormalities in soluble clotting factors are less common than thrombocytopenia, but also occur in this population. Low platelet counts and/or prolonged clotting times predispose critically ill patients to bleeding and may result in avoidance of diagnostic and therapeutic procedures. An in-depth understanding of the causes, limitations, and results of clotting time assays will help the clinician better identify and treat coagulopathy in critically ill patients.
patients receiving treatment of thrombotic disorders. 44 The risk of bleeding is dependent on a number of factors, including age, comorbidities, intensity of anticoagulant therapy, and type of surgery or procedure. 45 Patients undergoing prolonged, complex, or emergent procedures are at increased risk of signifi cant bleeding compared with those undergoing short, minor, or bedside procedures. Likewise, patients undergoing endoscopy may be at low risk for bleeding if only inspection and simple biopsy are undertaken, as opposed to a higher risk of bleeding for placement of percutaneous tubes, dilations, sphincterotomies, and fi ne needle aspirations. 46 In cases where the exact procedures required will not be known until endoscopy allows visualization, coagulation parameters should be managed to accommodate the most invasive procedure possible. Patients with signifi cant thrombotic disorders or dispositions may require reversal of therapeutic anticoagulation and bridging with short-lived anticoagulation during the periprocedure period. [47] [48] [49] Monitoring during this periprocedure period requires frequent hemostatic testing.
Because of the complexity of the issue, the values of PT, INR, and aPTT for which procedures are considered safe are largely driven by clinical opinion. Usually, an INR of 1.5 or lower is desired for surgery and many invasive bedside procedures. Some bedside procedures, such as paracenteses, thoracenteses, and nonsubclavian central venous catheter may be undertaken with higher INR levels, especially if required emergently. However, performance of even these procedures should be avoided if at all possible in patients with INR levels above 2. The INR can be lowered by administration of exogenous clotting factors, such as freshfrozen plasma, administration of vitamin K, or a combination of the two. Administration of vitamin K can be especially useful if the elevated INR is the result of receiving vitamin K antagonists (like coumadin) or nutritional defi ciencies. Despite the common practice of administering 10 mg, a smaller dose of vitamin K (1 or 2 mg) is often adequate to correct most PT and INR levels. Since heparin administration is the most common cause for an elevated aPTT, discontinuing the heparin is the most frequent therapy for correction. UFH infusions should be discontinued at least 1 h prior to the procedure, and LMWH should be held for 12 h prior to the procedure. Both UFH and LMWH can be restarted postprocedure once hemostasis is certain. If the effec ts of UFH, or to a lesser extent LMWH, must be reversed urgently, protamine sulfate, at a dose of 1 mg per 100 units of residual heparin, can be used as an antidote. Protamine does not, however, reverse the effects of fonda parinux.
